Skip to content
Clinical Trials – home

Geomedical Kft.

Research site

Hungary Jokai Utca 6, Kerulet, 1066 Budapest, Hungary

  • 13 trials recruiting
  • Colitis ulcerative · Crohn's disease · Arteriosclerosis
  • Adults and children

About Specializations

Geomedical Kft. in Budapest, Hungary specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Arteriosclerosis, Cardiac failure, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The department conducts studies aimed at improving outcomes for patients with heart failure, reducing risk in atherosclerotic cardiovascular disease, and managing hypertension. Research includes therapies that target lipoprotein(a) and strategies to prevent major adverse cardiovascular events.

  • Heart failure with preserved or mildly reduced ejection fraction
  • Atherosclerotic cardiovascular disease prevention
  • Hypertension and cardiovascular risk management
  • Lipoprotein(a) reduction therapies
  • Major adverse cardiovascular events (MACE) prevention

Geomedical Kft. collaborates with leading cardiology units in Budapest to advance treatment options for these conditions.

Digestive System Diseases

Clinical investigations focus on inflammatory bowel conditions such as Crohn's disease and ulcerative colitis, evaluating both induction and maintenance approaches to achieve remission and improve quality of life.

  • Induction therapy for moderate to severe Crohn's disease
  • Maintenance strategies for ulcerative colitis
  • Novel oral agents for inflammatory bowel disease
  • Biologic alternatives for refractory IBD
  • Patient‑reported outcome measures in IBD

The site’s gastroenterology team leverages its expertise to test new therapeutic options for these chronic gastrointestinal disorders.

Immune System Diseases

Trials address immune‑mediated skin disorders, including atopic dermatitis, chronic spontaneous urticaria, and chronic pruritus of unknown origin, seeking effective and safe treatments for patients who have limited options.

  • Targeted therapy for atopic dermatitis
  • Management of chronic spontaneous urticaria
  • Treatment of chronic pruritus of unknown origin
  • Immune modulation in skin disease
  • Safety of topical JAK inhibitors in youth

Geomedical Kft.’s immunology research integrates dermatology and systemic approaches to broaden therapeutic choices.

Nervous System Diseases

The site evaluates combination therapies for diabetic sensorimotor polyneuropathy, aiming to reduce neuropathic pain and improve functional outcomes for patients with diabetes‑related nerve damage.

  • Combination therapy for diabetic neuropathy
  • Pain reduction strategies in DSPN
  • Functional outcomes in peripheral neuropathy
  • Quality of life assessments in neuropathic patients
  • Safety of multi‑modal treatment approaches

The neurologic research program collaborates with endocrinology specialists to address the complex needs of this population.

Nutritional and Metabolic Diseases

Studies explore integrated interventions for type 2 diabetes, obesity, and related metabolic risk factors, including the use of adjunctive agents with established glucose‑lowering medications.

  • Adjunctive therapy with empagliflozin
  • Weight management in heart failure patients
  • Blood pressure control in diabetic populations
  • Metabolic risk reduction strategies
  • Integrated cardiovascular‑metabolic interventions

Geomedical Kft. leverages its metabolic clinic to test therapies that address both glycemic control and cardiovascular health.

Skin and Connective Tissue Diseases

Research includes trials for patients with moderate atopic dermatitis and severe itch, evaluating topical and systemic agents that aim to provide rapid symptom relief and long‑term disease control.

  • Topical JAK inhibitor trials in adolescents
  • Systemic therapy for severe eczema
  • Itch reduction outcomes
  • Safety of biologics in pediatric skin disease
  • Long‑term efficacy of new dermal agents

The dermatology division at Geomedical Kft. focuses on translating novel mechanisms into practical treatments for patients.

Immune System Phenomena

Investigations into fundamental immune system phenomena support the development of cytokine‑targeted therapies and biomarker‑driven approaches across multiple disease categories.

  • Cytokine blockade studies
  • Biomarker identification in inflammatory disorders
  • Immune response profiling
  • Mechanistic studies of novel immunomodulators
  • Translational immunology approaches

This foundational work underpins many of the site’s therapeutic programs and fosters collaborations with academic partners.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Jokai Utca 6, Kerulet1066 BudapestHungary
Recruiting now
13 trials
Conditions studied
12

More sites in BudapestHungary

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

19 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:XMAB942
  • Sponsor:Xencor Inc.

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Colitis ulcerative+2

Recruiting

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.